XomaZyme-Mel

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameXomaZyme-Mel

Drug Alias Nameantimelanoma antibody-ricin A conjugateXMMME-001-RTA

ClassificationBiologics > Protein drugs > ToxinBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Monoclonal antibody conjugateBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody conjugate

Mechanisms of ActionImmunostimulants

TargetsNot applicable

Therapy Area/IndicationsMelanoma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusDiscontinued (Phase 2 Clinical)

Highest Status in ChinaN/A

Originator CompaniesXoma Corp

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesXoma Corp

Active IndicationsN/A

Inactive IndicationsMelanoma

Other Information

ATC CodeN/A